Chapter 31. To Market, To Market -1988

Ong, Hwei Ling; Allen, Richard C.

doi:10.1016/s0065-7743(08)60553-9

Cited by 14 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the new approved drugs reported between 1983 and 1994 (Table ), − drugs of natural origin (N and ND) predominate (78%) in the area of antibacterials, while 61% of the 31 anticancer drugs (excluding the six biologics) are naturally-derived (N and ND) or are modeled on a natural product parent (S*). On the other hand, analgesic, antidepressant, antihistamine, anxiolytic, cardiotonic, and hypnotic drugs, together with the antifungal agents, are exclusively synthetic in origin, while 67.5% of the antiinflammatory drugs are synthetic.…”

Section: Resultsmentioning

confidence: 99%

“…Over the past 10 years, there has been a resurgence of interest in the investigation of natural materials as a source of potential, new chemotherapeutic agents, but there are now signs that this interest is once more waning in favor of new approaches to drug discovery, such as combinatorial chemistry and computer-based molecular modeling designs. In order to provide a more solid basis for the claims made for the importance of natural products in drug discovery and development, data on new drugs approved by either the United States Food and Drug Administration (FDA) or comparable entities in other countries, and reported mainly in the Annual Reports of Medicinal Chemistry for the years 1983−1994, − have been analyzed, predominantly in the areas of cancer and infectious diseases. Other data from a variety of sources have also been analyzed covering potential anticancer compounds reported to be in the pre-New Drug Application (NDA) phase up to the end of 1995.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Natural Products in Drug Discovery and Development

1997

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Natural Products in Drug Discovery and Development

1997

View full text Add to dashboard Cite

“…Against this backdrop, we now present an updated analysis of the role of natural products in the drug discovery and development process, dating from January 1981 through December 2014. As in our earlier analyses, − we have consulted the Annual Reports of Medicinal Chemistry , in this case from 1984 to 2014, − and to obtain more comprehensive coverage of the 1981–2014 time frame we have added data from the publication Drug News and Perspective, − the successor listings in Drugs of Today , − and searches of the Prous (now Thomson-Reuter’s Integrity ) database, as well as by including information from individual investigators. As in the last review, the biologics data prior to 2005 were updated using information culled from disparate sources that culminated in a 2005 review on biopharmaceutical drugs .…”

Section: Introductionmentioning

confidence: 99%

Natural Products as Sources of New Drugs from 1981 to 2014

Newman¹,

Cragg²

2016

J. Nat. Prod.

5,037

3,456

View full text Add to dashboard Cite

This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012. In the case of all approved therapeutic agents, the time frame has been extended to cover the 34 years from January 1, 1981, to December 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2014 for all approved antitumor drugs worldwide. As mentioned in the 2012 review, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the U.S. FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from around the 1940s to the end of 2014, of the 175 small molecules approved, 131, or 75%, are other than "S" (synthetic), with 85, or 49%, actually being either natural products or directly derived therefrom. In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore it is considered that this area of natural product research should be expanded significantly.

show abstract

“…Against this backdrop, we now present an updated analysis of the role of natural products in the drug discovery and development process, dating from January 1981 through December 2010. As in our earlier analyses, − we have consulted the Annual Reports of Medicinal Chemistry , in this case from 1984 to 2010, − and have produced a more comprehensive coverage of the 1981–2010 time frame through addition of data from the publication Drug News and Perspective − and searches of the Prous (now Thomson-Reuter’s Integrity ) database, as well as by including information from individual investigators. As in the last review, biologics data prior to 2005 were updated using information culled from disparate sources that culminated in a 2005 review on biopharmaceutical drugs .…”

Section: Introductionmentioning

confidence: 99%

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

2012

View full text Add to dashboard Cite

This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003 and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1st 1981 to December 31st 2010 for all diseases world-wide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs world-wide. We have continued to utilize our secondary subdivision of a “natural product mimic” or “NM” to join the original primary divisions, and have added a new designation “natural product botanical” or “NB” to cover those botanical “defined mixtures” that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131 or 74.8% are other than “S” (synthetic), with 85 or 48.6% actually being either natural products or directly derived there from. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures, and have been used very successfully in the optimization of many recently approved agents, we are only able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the “host from whence it was isolated”, and therefore we consider that this area of natural product research should be expanded significantly.

show abstract

Chapter 31. To Market, To Market -1988

Cited by 14 publications

References 60 publications

Natural Products in Drug Discovery and Development

Natural Products in Drug Discovery and Development

Natural Products as Sources of New Drugs from 1981 to 2014

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

Contact Info

Product

Resources

About